Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28466043 | 0.84 | CTSD (0.64) | CTSDLMNAPKMPOLBREN | |
| SCHEMBL28466047 | 0.84 | CTSD (0.64) | CTSDLMNAPKMPOLBREN | |
| SCHEMBL16296386 | 0.83 | CTSD (0.71) | CTSDLMNAPKMRENMMP8 | |
| Hydrochloric Acid SCHEMBL17764791 | 0.82 | CTSD (0.69) | CTSDLMNAPKMRENMMP8 | |
| SCHEMBL16296098 | 0.80 | CTSD (0.78) | CTSDLMNAPKMREN | |
| SCHEMBL20725223 | 0.80 | CTSD (0.78) | CTSDLMNAPKMREN | |
| SCHEMBL20506434 | 0.80 | CTSD (0.78) | CTSDLMNAPKMREN | |
| SCHEMBL20506520 | 0.79 | CTSD (0.76) | CTSDMMP1MMP3 | |
| SCHEMBL20725211 | 0.79 | CTSD (0.76) | CTSDMMP1MMP3 | |
| SCHEMBL16295137 | 0.79 | CTSD (0.76) | CTSDMMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202418-B2 | Hydroxy-ethylene derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2019-02-12 | — | — | US | claimed |
| EP-3008037-B1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2018-09-26 | — | — | EP | claimed |
| US-20160145297-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | claimed |
| EP-3008037-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | Merck Patent GmbH (DE) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198372-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | WO | claimed |
| US-10202418-B2 | Hydroxy-ethylene derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| EP-3008037-B1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-20160145297-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202418-B2 | Hydroxy-ethylene derivatives for the treatment of arthrosis | CTSD, CTSE, CTSB | CTSD 1/4885LMNA 2218/4885PKM 2328/4885 |
| US-20160145297-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSE, CTSB | CTSD 1/4885LMNA 2218/4885PKM 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.